Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM A
                                                                                 (N=30)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

    All System Organ Classes
       All Adverse Events                                        22 ( 73.3%)   8 ( 26.7%)   0 (  0.0%)

    Gastrointestinal disorders
       Diarrhoea                                                  1 (  3.3%)   0 (  0.0%)   0 (  0.0%)
       Stomach Discomfort                                         1 (  3.3%)   0 (  0.0%)   0 (  0.0%)
       Toothache                                                  1 (  3.3%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Rash Pustular                                              1 (  3.3%)   0 (  0.0%)   0 (  0.0%)
       Respiratory Tract Infection                                1 (  3.3%)   0 (  0.0%)   0 (  0.0%)
       Rhinitis                                                   0 (  0.0%)   1 (  3.3%)   0 (  0.0%)
       Upper Respiratory Fungal Infection                         0 (  0.0%)   1 (  3.3%)   0 (  0.0%)
       Upper Respiratory Tract Infection                          1 (  3.3%)   0 (  0.0%)   0 (  0.0%)
       Wound Infection                                            0 (  0.0%)   1 (  3.3%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Heat Cramps                                                1 (  3.3%)   0 (  0.0%)   0 (  0.0%)
       Procedural Pain                                            0 (  0.0%)   1 (  3.3%)   0 (  0.0%)

    Investigations
       Blood Potassium Decreased                                  0 (  0.0%)   1 (  3.3%)   0 (  0.0%)
       Blood Triglycerides Increased                              1 (  3.3%)   0 (  0.0%)   0 (  0.0%)
       Vitamin D Decreased                                        1 (  3.3%)   0 (  0.0%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 1 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM B
                                                                                 (N=19)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

    All System Organ Classes
       All Adverse Events                                         9 ( 47.4%)  10 ( 52.6%)   0 (  0.0%)

    Gastrointestinal disorders
       Diarrhoea                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Stomach Discomfort                                         0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Toothache                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Rash Pustular                                              0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Respiratory Tract Infection                                0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Rhinitis                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Upper Respiratory Fungal Infection                         0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Upper Respiratory Tract Infection                          2 ( 10.5%)   0 (  0.0%)   0 (  0.0%)
       Wound Infection                                            0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Heat Cramps                                                0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Procedural Pain                                            0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Investigations
       Blood Potassium Decreased                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Blood Triglycerides Increased                              0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Vitamin D Decreased                                        0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 2 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM C
                                                                                 (N=10)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

    All System Organ Classes
       All Adverse Events                                         4 ( 40.0%)   6 ( 60.0%)   0 (  0.0%)

    Gastrointestinal disorders
       Diarrhoea                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Stomach Discomfort                                         0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Toothache                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Rash Pustular                                              0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Respiratory Tract Infection                                0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Rhinitis                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Upper Respiratory Fungal Infection                         0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Upper Respiratory Tract Infection                          2 ( 20.0%)   0 (  0.0%)   0 (  0.0%)
       Wound Infection                                            0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Heat Cramps                                                0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Procedural Pain                                            0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Investigations
       Blood Potassium Decreased                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Blood Triglycerides Increased                              0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Vitamin D Decreased                                        0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 3 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM D
                                                                                 (N=16)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

    All System Organ Classes
       All Adverse Events                                         7 ( 43.8%)   8 ( 50.0%)   1 (  6.2%)

    Gastrointestinal disorders
       Diarrhoea                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Stomach Discomfort                                         0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Toothache                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Rash Pustular                                              0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Respiratory Tract Infection                                0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Rhinitis                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Upper Respiratory Fungal Infection                         0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Upper Respiratory Tract Infection                          1 (  6.2%)   0 (  0.0%)   0 (  0.0%)
       Wound Infection                                            0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Heat Cramps                                                0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Procedural Pain                                            0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Investigations
       Blood Potassium Decreased                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Blood Triglycerides Increased                              0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Vitamin D Decreased                                        0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 4 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM A
                                                                                 (N=30)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯


    Musculoskeletal and connective tissue disorders
       Joint Swelling                                             0 (  0.0%)   1 (  3.3%)   0 (  0.0%)
       Myalgia                                                    0 (  0.0%)   1 (  3.3%)   0 (  0.0%)
       Pain In Extremity                                          1 (  3.3%)   0 (  0.0%)   0 (  0.0%)

    Nervous system disorders
       Dizziness                                                  1 (  3.3%)   0 (  0.0%)   0 (  0.0%)
       Headache                                                  10 ( 33.3%)   1 (  3.3%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Nasal Congestion                                           1 (  3.3%)   0 (  0.0%)   0 (  0.0%)

    Gastrointestinal disorders
       Cheilitis                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    General disorders and administration site conditions
       Application Site Erythema                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Hepatobiliary disorders
       Gallbladder Disorder                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Paronychia                                                 0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 5 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM B
                                                                                 (N=19)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯


    Musculoskeletal and connective tissue disorders
       Joint Swelling                                             0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Myalgia                                                    0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Pain In Extremity                                          0 (  0.0%)   1 (  5.3%)   0 (  0.0%)

    Nervous system disorders
       Dizziness                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Headache                                                   1 (  5.3%)   1 (  5.3%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Nasal Congestion                                           0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Gastrointestinal disorders
       Cheilitis                                                  0 (  0.0%)   1 (  5.3%)   0 (  0.0%)

    General disorders and administration site conditions
       Application Site Erythema                                  1 (  5.3%)   0 (  0.0%)   0 (  0.0%)

    Hepatobiliary disorders
       Gallbladder Disorder                                       0 (  0.0%)   1 (  5.3%)   0 (  0.0%)

    Infections and infestations
       Paronychia                                                 0 (  0.0%)   1 (  5.3%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 6 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM C
                                                                                 (N=10)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯


    Musculoskeletal and connective tissue disorders
       Joint Swelling                                             0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Myalgia                                                    0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Pain In Extremity                                          0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Nervous system disorders
       Dizziness                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Headache                                                   0 (  0.0%)   1 ( 10.0%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Nasal Congestion                                           0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Gastrointestinal disorders
       Cheilitis                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    General disorders and administration site conditions
       Application Site Erythema                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Hepatobiliary disorders
       Gallbladder Disorder                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Paronychia                                                 0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 7 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM D
                                                                                 (N=16)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯


    Musculoskeletal and connective tissue disorders
       Joint Swelling                                             0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Myalgia                                                    0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Pain In Extremity                                          0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Nervous system disorders
       Dizziness                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Headache                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Nasal Congestion                                           0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Gastrointestinal disorders
       Cheilitis                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    General disorders and administration site conditions
       Application Site Erythema                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Hepatobiliary disorders
       Gallbladder Disorder                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Paronychia                                                 0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 8 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM A
                                                                                 (N=30)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

       Sinusitis                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Urinary Tract Infection                                    0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Fall                                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Cough                                                      0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Skin and subcutaneous tissue disorders
       Erythema                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Skin Discomfort                                            0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Surgical and medical procedures
       Cholecystectomy                                            0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Skin Lesion Excision                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    General disorders and administration site conditions
       Influenza Like Illness                                     0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Bronchitis                                                 0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Nail Infection                                             0 (  0.0%)   0 (  0.0%)   0 (  0.0%)


Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 9 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM B
                                                                                 (N=19)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

       Sinusitis                                                  1 (  5.3%)   0 (  0.0%)   0 (  0.0%)
       Urinary Tract Infection                                    0 (  0.0%)   2 ( 10.5%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Fall                                                       1 (  5.3%)   0 (  0.0%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Cough                                                      0 (  0.0%)   1 (  5.3%)   0 (  0.0%)

    Skin and subcutaneous tissue disorders
       Erythema                                                   2 ( 10.5%)   0 (  0.0%)   0 (  0.0%)
       Skin Discomfort                                            1 (  5.3%)   0 (  0.0%)   0 (  0.0%)

    Surgical and medical procedures
       Cholecystectomy                                            0 (  0.0%)   1 (  5.3%)   0 (  0.0%)
       Skin Lesion Excision                                       0 (  0.0%)   1 (  5.3%)   0 (  0.0%)

    General disorders and administration site conditions
       Influenza Like Illness                                     0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Bronchitis                                                 0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Nail Infection                                             0 (  0.0%)   0 (  0.0%)   0 (  0.0%)


Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 10 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM C
                                                                                 (N=10)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

       Sinusitis                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Urinary Tract Infection                                    0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Fall                                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Cough                                                      0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Skin and subcutaneous tissue disorders
       Erythema                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Skin Discomfort                                            0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Surgical and medical procedures
       Cholecystectomy                                            0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Skin Lesion Excision                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    General disorders and administration site conditions
       Influenza Like Illness                                     1 ( 10.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Bronchitis                                                 0 (  0.0%)   2 ( 20.0%)   0 (  0.0%)
       Nail Infection                                             0 (  0.0%)   1 ( 10.0%)   0 (  0.0%)


Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 11 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM D
                                                                                 (N=16)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

       Sinusitis                                                  0 (  0.0%)   1 (  6.2%)   0 (  0.0%)
       Urinary Tract Infection                                    0 (  0.0%)   1 (  6.2%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Fall                                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Cough                                                      0 (  0.0%)   1 (  6.2%)   0 (  0.0%)

    Skin and subcutaneous tissue disorders
       Erythema                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Skin Discomfort                                            0 (  0.0%)   1 (  6.2%)   0 (  0.0%)

    Surgical and medical procedures
       Cholecystectomy                                            0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Skin Lesion Excision                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    General disorders and administration site conditions
       Influenza Like Illness                                     0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Bronchitis                                                 0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Nail Infection                                             0 (  0.0%)   0 (  0.0%)   0 (  0.0%)


Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 12 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM A
                                                                                 (N=30)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

    Nervous system disorders
       Burning Sensation                                          0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Reproductive system and breast disorders
       Menstrual Discomfort                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Skin and subcutaneous tissue disorders
       Pruritus                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Tinea Pedis                                                0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Muscle Injury                                              0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Musculoskeletal and connective tissue disorders
       Back Pain                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Nervous system disorders
       Sciatica                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Sinus Congestion                                           0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Throat Irritation                                          0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 13 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM B
                                                                                 (N=19)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

    Nervous system disorders
       Burning Sensation                                          0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Reproductive system and breast disorders
       Menstrual Discomfort                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Skin and subcutaneous tissue disorders
       Pruritus                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Infections and infestations
       Tinea Pedis                                                0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Muscle Injury                                              0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Musculoskeletal and connective tissue disorders
       Back Pain                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Nervous system disorders
       Sciatica                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Sinus Congestion                                           0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Throat Irritation                                          0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 14 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM C
                                                                                 (N=10)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

    Nervous system disorders
       Burning Sensation                                          1 ( 10.0%)   0 (  0.0%)   0 (  0.0%)

    Reproductive system and breast disorders
       Menstrual Discomfort                                       0 (  0.0%)   1 ( 10.0%)   0 (  0.0%)

    Skin and subcutaneous tissue disorders
       Pruritus                                                   0 (  0.0%)   1 ( 10.0%)   0 (  0.0%)

    Infections and infestations
       Tinea Pedis                                                0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Muscle Injury                                              0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Musculoskeletal and connective tissue disorders
       Back Pain                                                  0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Nervous system disorders
       Sciatica                                                   0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Sinus Congestion                                           0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
       Throat Irritation                                          0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 15 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM D
                                                                                 (N=16)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

    Nervous system disorders
       Burning Sensation                                          0 (  0.0%)   0 (  0.0%)   1 (  6.2%)

    Reproductive system and breast disorders
       Menstrual Discomfort                                       0 (  0.0%)   0 (  0.0%)   0 (  0.0%)

    Skin and subcutaneous tissue disorders
       Pruritus                                                   1 (  6.2%)   2 ( 12.5%)   0 (  0.0%)

    Infections and infestations
       Tinea Pedis                                                0 (  0.0%)   1 (  6.2%)   0 (  0.0%)

    Injury, poisoning and procedural complications
       Muscle Injury                                              0 (  0.0%)   1 (  6.2%)   0 (  0.0%)

    Musculoskeletal and connective tissue disorders
       Back Pain                                                  1 (  6.2%)   0 (  0.0%)   0 (  0.0%)

    Nervous system disorders
       Sciatica                                                   1 (  6.2%)   0 (  0.0%)   0 (  0.0%)

    Respiratory, thoracic and mediastinal disorders
       Sinus Congestion                                           1 (  6.2%)   0 (  0.0%)   0 (  0.0%)
       Throat Irritation                                          1 (  6.2%)   0 (  0.0%)   0 (  0.0%)

Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 16 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM A
                                                                                 (N=30)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

       Upper Respiratory Tract Congestion                         0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
























Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 17 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM B
                                                                                 (N=19)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

       Upper Respiratory Tract Congestion                         0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
























Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 18 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM C
                                                                                 (N=10)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

       Upper Respiratory Tract Congestion                         0 (  0.0%)   0 (  0.0%)   0 (  0.0%)
























Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 19 of 20
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                  ARM D
                                                                                 (N=16)
                                                                 ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
    System Organ Class
       Preferred Term                                                Mild        Mod**        Severe
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

       Upper Respiratory Tract Congestion                         1 (  6.2%)   0 (  0.0%)   0 (  0.0%)
























Date Produced: Time ;  SAS Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 20 of 20
